Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px

Document › Details

Ablynx N.V.. (5/20/15). "Press Release: Ablynx Announces Final Terms of the EUR 100 Million Senior Unsecured Convertible Bonds Due May 2020 [Not for US, AU, CA, ZA or JP et al.]". Ghent.

	Organisation	Ablynx N.V. (Euronext Brussels: ABLX, Nasdaq: ABLX)
	Group	Ablynx (Group)
	Organisation 2	Bank of America Merrill Lynch (BofA Merrill Lynch, marketing name of Bank of America Corporation)
	Product	Nanobodies®
	Product 2	investment banking
	Index term	Ablynx–SEVERAL: credit, 201505–202005 senior unsecured convertible bonds €100m at 3.25% due May 2020
	Person	Moses, Edwin (Ablynx 200603– CEO before non-exec Board Member 200411– before Oxford Asymmetry)
	Person 2	Elliott, Mary-Jane (Consilium SC 201307– Managing Partner + Co-founder before M:Communications)

Original document
accessed by [iito] on 2015-07-22

Record changed: 2016-03-19

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for Ablynx (Group)

[1] Silence Therapeutics plc. (8/5/19). "Press Release: Silence Therapeutics Appoints Jørgen Wittendorff as Head of Manufacturing". London....
[2] Virion Biotherapeutics Ltd.. (12/17/18). "Press Release: Virion Biotherapeutics Appoints Edwin Moses as Chairman of the Board and Guido Dietrich as Head of Manufacturing". London....
[3] Confo Therapeutics N.V.. (12/6/18). "Press Release: Confo Therapeutics Appoints Frank Landolt as Its Chief Counsel Legal & Intellectual Property". Ghent....
[4] Photocure ASA. (9/20/18). "Press Release: Daniel Schneider Appointed Chief Executive Officer". Oslo....
[5] Sanofi S.A.. (9/3/18). "Press Release: Cablivi (caplacizumab) Approved in Europe for Adults with Acquired Thrombotic Thrombocytopenic Purpura (aTTP)". Paris....
[6] Sanofi S.A.. (6/19/18). "Press Release: Sanofi Completes Its Acquisition of Ablynx Following the Expiration of the Squeeze-out Procedure". Paris & Ghent....
[7] Ablynx N.V.. (3/26/18). "Press Release: Ablynx Announces Topline Results from the Phase II Study of Vobarilizumab in Patients with Systemic Lupus Erythematosus". Ghent....
[8] Ablynx N.V.. (3/2/18). "Press Release: Ablynx Commences Dosing in Its Phase II Study of ALX-0171 in Hospitalised Japanese Infants with a RSV Infection". Ghent....
[9] Ablynx N.V.. (2/7/18). "Press Release: Ablynx Announces Board Changes". Ghent....
[10] Sanofi S.A.. (1/29/18). "Press Release: Sanofi to Acquire Ablynx for €3.9 Billion". Paris & Ghent....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

» top